DrugBank ID: db00159
Synonymous :(5z,8z,11z,14z,17z)-5,8,11,14,17-eicosapentaenoic acid | (5z,8z,11z,14z,17z)-eicosapentaenoate | (5z,8z,11z,14z,17z)-eicosapentaenoic acid | (5z,8z,11z,14z,17z)-icosapentaenoic acid | (all-z)-5,8,11,14,17-eicosapentaenoic acid | 5,8,11,14,17-eicosapentaenoic acid | 5,8,11,14,17-icosapentaenoic acid | all-cis-5,8,11,14,17-eicosapentaenoic acid | all-cis-5,8,11,14,17-icosapentaenoic acid | all-cis-icosa-5,8,11,14,17-pentaenoic acid | cis-5,8,11,14,17-eicosapentaenoic acid | cis-5,8,11,14,17-epa | cis-delta(5,8,11,14,17)-eicosapentaenoic acid | eicosapentaenoic acid | epa | icosapent | icosapentaenoic acid | icosapento | icosapentum | timnodonic acid
Drug Sentece Context
Table 1. Analysis of context sentence of icosapent gene in 2 abstracts.
|32984987||Our study revealed that only cilostazol has the most favorable binding interaction on Mpro (PDB ID: 6LU7) and cilostazol, iloprost, epoprostenol, prasugrel, and icosapent ethyl have a higher binding affinity on spike glycoprotein (S) (PDB ID: 6VYB) compared with recent anti-CoVID-19.|
|33009957||The studies reviewed include clinical trials on novel RNA interference-based lipid-lowering therapies AKCEA-APOCIII-LRx and vupanorsen (AKCEA-ANGPTL3-LRx); the EVAPORATE trial assessing the effects of icosapent ethyl on coronary plaque volume progression; the LoDoCo2 trial evaluating the efficacy of low-dose colchicine in cardiovascular disease risk reduction among patients with chronic coronary artery disease; as well as the EMPEROR-Reduced trial evaluating cardiovascular and renal outcomes with empagliflozin in patients with heart failure and reduced ejection fraction.|
|33033686||Icosapent ethyl (IPE) is an Omega-3 fatty acid derivative that has been shown to significantly reduce cardiovascular mortality and is used as an adjunct to statin therapy.|